Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Castle Biosciences ( (CSTL) ).
On August 5, 2025, Castle Biosciences, Inc. adopted amended and restated bylaws, introducing several changes to enhance governance and operational clarity. These changes include revisions to stockholder meeting procedures, nomination processes, and director and officer indemnification, potentially impacting the company’s governance structure and stakeholder interactions.
The most recent analyst rating on (CSTL) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Castle Biosciences stock, see the CSTL Stock Forecast page.
Spark’s Take on CSTL Stock
According to Spark, TipRanks’ AI Analyst, CSTL is a Neutral.
Castle Biosciences’ overall score is driven by its financial performance challenges, including declining revenue growth and profitability. While the earnings call provided a positive outlook with increased revenue guidance, technical indicators suggest a bearish trend. Valuation remains a concern due to negative earnings and lack of dividends.
To see Spark’s full report on CSTL stock, click here.
More about Castle Biosciences
Castle Biosciences, Inc. operates in the biotechnology industry, focusing on developing and commercializing diagnostic and prognostic tests for dermatologic cancers and other diseases. The company aims to provide personalized medicine solutions by offering tests that guide treatment decisions and improve patient outcomes.
Average Trading Volume: 459,395
Technical Sentiment Signal: Sell
Current Market Cap: $573.2M
Learn more about CSTL stock on TipRanks’ Stock Analysis page.